
Human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) are widely used in regenerative medicine, but in vitro expansion alters their molecular and functional properties. Understanding replicative senescence trajectories is critical for optimizing cell manufacturing. We performed longitudinal RNA sequencing across passages P3, P6, P9, P12, and P15, using P6 as a clinical reference. Transcriptomic dynamics were bioinformatically analyzed and validated by targeted quantitative real-time PCR. Functional assays assessed senescence-associated β-galactosidase (SA-β-gal) activity, mitochondrial membrane potential, iron accumulation, and glucose uptake. Transcriptomic profiling revealed progressive, passage-dependent divergence with an inflection point after P9. Late-passage cells (P12, P15) exhibited coordinated upregulation of proinflammatory pathways (TNFα, IL-17, and MAPK) and senescence programs, alongside downregulation of oxidative phosphorylation and autophagy. Functional validations confirmed that P12 cells acquired a senescent phenotype: enhanced SA-β-gal, mitochondrial depolarization, iron overload, and a glycolytic shift. Molecular analyses corroborated increased expression of senescence-associated secretory phenotype factors (IL6, CCL2) and glucose transporters (SLC2A1), with suppression of mitochondrial genes (MT-CO2, MT-ND4). P6 cells maintained stable profiles and robust integrity. Serial passaging drives hUC-MSCs toward senescence through bidirectional reprogramming of inflammation and metabolism. Our findings identify P6–P9 as a safe manufacturing window and propose metabolic and iron-related markers for quality control of clinical-grade MSCs, ensuring therapeutic potency.
Bone aging is characterized by a progressive decline in skeletal regenerative capacity, driven by stem-cell senescence, chronic inflammation, impaired vascularization, metabolic dysfunction, and alterations in the bone marrow niche. These changes contribute to osteoporosis, delayed fracture healing, and reduced bone quality in older individuals. Stem cell-based therapies have emerged as promising strategies to restore bone regeneration, with investigations focusing on mesenchymal stromal cells, skeletal stem cells, adipose-derived stromal cells, induced pluripotent stem cell-derived osteogenic progenitors, and cell-free approaches such as extracellular vesicles and secretomes. This narrative review examines the biological mechanisms underlying bone aging, the impact of the aged microenvironment on stem-cell function, and current approaches to rejuvenate skeletal regeneration. We discuss advances in tissue engineering, including biomaterials, 3D-printed scaffolds, controlled-release systems, and multifunctional constructs designed to modulate inflammation, enhance angiogenesis, and improve osteogenesis. Preclinical studies consistently demonstrate beneficial effects on bone formation, microarchitecture, and repair; however, translation to clinical practice remains limited. Human studies have primarily focused on fracture nonunion and focal bone defects, showing encouraging safety and feasibility but insufficient evidence for systemic treatment of age-related skeletal fragility. Major barriers include cellular heterogeneity, manufacturing and regulatory challenges, inadequate potency assays, and the complexity of the aged bone niche. Future success will likely depend on integrated therapeutic strategies that simultaneously target progenitor-cell dysfunction and the local microenvironment while ensuring reproducible, scalable, and clinically meaningful outcomes. These advances may pave the way toward effective regenerative therapies for osteoporosis and age-related bone loss.
Patient-derived induced pluripotent stem cells (iPSCs) provide a renewable model for studying acute myeloid leukemia (AML), but whether AML-iPSCs faithfully preserve the functional heterogeneity of genetically distinct AML clones remains unclear. Here, we functionally characterized a genetically defined AML-iPSC resource comprising 34 AML-iPSC lines from 11 AML patients, with complementary assays performed across partially overlapping subsets of lines. AML-iPSC lines were classified as aberration-positive (Ab+) or aberration-negative (Ab-) based on retention of the clinically defining patient-specific leukemia-associated genetic abnormalities. Representative Ab+ and Ab- AML-iPSC lines derived from donor hematopoietic cells exhibited comparable differentiation capacity across nonhematopoietic lineages, whereas Ab+ AML-iPSC lines demonstrated reduced hematopoietic differentiation, as determined by phenotypic analysis and functional colony-forming assays. Across overlapping subsets of AML-iPSC lines, these clone-specific hematopoietic phenotypes were conserved across four independent differentiation platforms, supporting that they reflect stable clone-specific properties rather than methodological artifacts. Residual hematopoietic progenitors derived from Ab+ AML-iPSC lines retained leukemic features, including persistence of leukemia-associated genetic abnormalities, immature blast-like morphology, and enhanced serial replating capacity indicative of self-renewal-associated properties. In a representative paired patient model, these progenitors also demonstrated persistent myeloid-skewed hematopoietic output following xenotransplantation. Together, these findings establish a renewable platform for mechanistic studies investigating how clonal heterogeneity contributes to disease evolution and therapeutic resistance in AML following pluripotent reprogramming.
Bone marrow-derived leptin receptor-expressing (LepR+) stromal cells (LepR+ BMSCs) have been identified as the primary source of osteoblasts, adipocytes, and fibroblasts in the bone marrow, and they play key roles in the maintenance of the bone marrow microenvironment; however, research on the fate and immunomodulatory changes of human LepR+ BMSCs is limited. Here, we isolated LepR+ BMSCs from a young donor and studied their fate changes of osteogenic, adipogenic, myogenic differentiation, and immunomodulation with or without CXM102, a novel compound that we have previously demonstrated its anti-osteoporotic effects in mice. Our results showed that CXM102 facilitated a preferential lineage shift toward osteogenesis from adipogenesis of LepR+ BMSCs in vitro, as evidenced by increased RUNX 2 expression and decreased PPAR gamma in a bivalent differentiation system. Moreover, interleukin-6 (IL-6), interleukin-1 beta (IL-1 beta), and tumor necrosis factor-alpha (TNF-alpha) were markedly downregulated in HS-5 stromal cells cocultured with conditioned medium from CXM102-treated LepR+ BMSCs. Furthermore, CXM102 also inhibited collagen I deposition in LepR+ BMSCs when induced into myogenesis. These results demonstrated that CXM102 could promote osteogenesis, but inhibit adipogenesis and myogenesis of LepR+ BMSCs, while also showing benign immunomodulation in vitro.
Stem cell-associated microRNAs (miRNAs) have emerged as pivotal regulators of osteogenesis, influencing lineage commitment, differentiation, and skeletal tissue homeostasis. Their dysregulation has been increasingly linked to a spectrum of osteogenic disorders, including osteoporosis, osteoarthritis, and impaired fracture healing. This narrative review synthesizes current evidence on the diagnostic potential of stem cell-associated miRNAs in bone-related pathologies. We highlight their roles in modulating osteoblast and osteoclast activity, maintaining mesenchymal stem cell fate, and orchestrating signaling pathways such as Wnt/β-catenin, bone morphogenetic protein, and Notch. Particular emphasis is placed on circulating miRNAs as minimally invasive biomarkers, offering prospects for early detection, disease stratification, and monitoring therapeutic response. Furthermore, we discuss methodological advances in miRNA profiling, challenges in clinical translation, and the need for standardized validation frameworks. By integrating molecular insights with translational perspectives, this review underscores the promise of stem cell-associated miRNAs as diagnostic tools in osteogenic disorders, while identifying critical gaps that must be addressed to enable their incorporation into precision medicine strategies.